Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05765175 · ClinicalTrials.gov registry record · NA
Cardiac RADIoablation Versus Repeat Catheter Ablation: a Pivotal Randomized Clinical Trial Evaluating Safety and Efficacy for Patients With High-risk Refractory Ventricular Tachycardia (RADIATE-VT)
A NA study of Tachycardia, Ventricular, sponsored by Varian, a Siemens Healthineers Company.
- Recruiting
- Registry status
- NA
- Development phase
- 380
- Enrollment target
- 10
- Study locations
NCT05765175: Recruiting NA study of Tachycardia, Ventricular, sponsored by Varian, a Siemens Healthineers Company.
NCT05765175 is a NA study of Tachycardia, Ventricular that is actively recruiting participants, run by Varian, a Siemens Healthineers Company. The registered enrollment target is 380 participants, above the 206-participant average among 4 other Tachycardia, Ventricular trials with a reported enrollment target (84% higher). The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05765175, a NA study of Tachycardia, Ventricular, is actively recruiting participants, sponsored by Varian, a Siemens Healthineers Company.
- RECRUITING
- Registry status
- NA
- Development phase
- 380 participants
- Enrollment target
- 10
- Study locations
Study Summary
RADIATE-VT is a pivotal, multicenter, randomized trial comparing safety and efficacy between cardiac radioablation (CRA) using the Varian CRA System and repeat catheter ablation (CA), for patients with high-risk refractory ventricular tachycardia (VT) who have experienced VT recurrence after CA and are candidates for additional CA.
Primary Outcome
Freedom from treatment-attributed (i.e., probably or definitely related) serious adverse events (SAEs), evaluated from treatment through 12 months post-treatment.
Conditions Studied
Interventions
- DEVICE Varian Cardiac Radioablation (CRA)
- PROCEDURE Catheter Ablation (CA)
Study Locations (10)
Pennsylvania
- University of Pennsylvania - Philadelphia
- University of Pittsburgh Medical Center - Pittsburgh
California
- Cedars-Sinai Medical Center - Los Angeles
Connecticut
- Hartford Hospital - Hartford
Massachusetts
- Brigham & Women's Hospital - Boston
Minnesota
- Mayo Clinic - Rochester
Missouri
- Washington University - St Louis
Ohio
- The Ohio State University - Columbus
South Carolina
- Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 380 participants |
| Start Date | 2023-04-21 |
| Est. Completion | 2030-05 |
| Phase | NA |
What NCT05765175 shows while recruiting
NCT05765175 is an interventional study that assigns participants to a tested intervention. The registered 380 participants enrollment target is mid-sized for trials with a published cap, above the 206-participant average among 4 other Tachycardia, Ventricular trials with a reported enrollment target (84% higher).
The record links to 1 condition, with Tachycardia, Ventricular appearing as the primary indexed condition, and to 2 interventions - of which Varian Cardiac Radioablation (CRA) is the first listed.
NCT05765175 lists 10 locations in 9 states (Pennsylvania, California, Connecticut).
Frequently Asked Questions
What is clinical trial NCT05765175 about?
NCT05765175 is a clinical study titled "Cardiac RADIoablation Versus Repeat Catheter Ablation: a Pivotal Randomized Clinical Trial Evaluating Safety and Efficacy for Patients With High-risk Refractory Ventricular Tachycardia (RADIATE-VT)". RADIATE-VT is a pivotal, multicenter, randomized trial comparing safety and efficacy between cardiac radioablation (CRA) using the Varian CRA System and repeat catheter ablation (CA), for patients with high-risk refractory ventricular tachycardia (VT) who have experienced VT recurrence after CA and ...
What is the current status of trial NCT05765175?
This trial is currently recruiting. It is a NA study. The enrollment target is 380 participants. The study started on 2023-04-21. Estimated completion is 2030-05.
What conditions does trial NCT05765175 study?
This clinical trial studies the following conditions: Tachycardia, Ventricular.
What interventions are being tested in trial NCT05765175?
The interventions under investigation include: Varian Cardiac Radioablation (CRA) (DEVICE), Catheter Ablation (CA) (PROCEDURE).
Who is sponsoring clinical trial NCT05765175?
This trial is sponsored by Varian, a Siemens Healthineers Company, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05765175 being conducted?
This trial has 10 study locations across California, Connecticut, Massachusetts, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tachycardia, Ventricular
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effectiveness of the EMPOWER™ Modular Pacing System and EMBLEM™ Subcutaneous ICD to Communicate Antitachycardia Pacing
ACTIVE NOT RECRUITING · NA
-
S-ICD® System IDE Clinical Study
COMPLETED · NA
-
CyberHeart's Cardiac Arrhythmia Ablation Treatment: Patients With Refractory Ventricular Tachycardia/Fibrillation
COMPLETED · NA
-
Automatic External Defibrillation Monitoring in Cardiac Arrest
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04560673 · 380 participants · Phase 2
Duloxetine and Neurofeedback Training for the Treatment of Chemotherapy Induced Peripheral Neuropathy
- NCT04777357 · 380 participants · Phase 3
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
- NCT04821154 · 380 participants
Persona Revision Knee System Outcomes
- NCT05102019 · 380 participants · NA
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI